The use of warfarin for DVT prophylaxis following hip and knee arthroplasty: how often are patients within their target INR range?

Use of dabigatran vs. warfarin with low-molecular-weight heparin bridging in catheter ablation for atrial fibrillation patients with a low CHADS2 score. Biomed Rep (2017) 0.75

Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am (2007) 24.18

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 16.17

Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65

Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.55

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94

Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.99

Systematic overview of warfarin and its drug and food interactions. Arch Intern Med (2005) 5.86

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54

Clinical characteristics and outcomes of Medicare patients undergoing total hip arthroplasty, 1991-2008. JAMA (2011) 3.09

Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. JAMA (1992) 2.27

Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis (2007) 2.12

Thrombosis prevention after total hip arthroplasty: a prospective, randomized trial comparing a mobile compression device with low-molecular-weight heparin. J Bone Joint Surg Am (2010) 1.79

In hospital complications after total joint arthroplasty. J Arthroplasty (2008) 1.69

The effectiveness of warfarin dosing from a nomogram compared with house staff dosing. J Arthroplasty (2007) 1.67

Current guidelines for total joint VTE prophylaxis: dawn of a new day. J Bone Joint Surg Br (2012) 1.57

Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. J Thromb Haemost (2008) 1.51

Does "excessive" anticoagulation predispose to periprosthetic infection? J Arthroplasty (2007) 1.45

Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J (2011) 1.38

American academy of orthopaedic surgeons clinical practice guideline on. Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. J Bone Joint Surg Am (2009) 1.34

Unplanned readmission after total joint arthroplasty: rates, reasons, and risk factors. J Bone Joint Surg Am (2013) 1.32

Meta-analysis of cause of death following total joint replacement using different thromboprophylaxis regimens. J Bone Joint Surg Br (2012) 1.07

Failure of the American College of Chest Physicians-1A protocol for lovenox in clinical outcomes for thromboembolic prophylaxis. J Arthroplasty (2007) 1.00

Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States. Clin Ther (2002) 0.95

Complications related to therapeutic anticoagulation in total hip arthroplasty. J Arthroplasty (2013) 0.86

Assessing evidence of interaction between smoking and warfarin: a systematic review and meta-analysis. Chest (2011) 0.85

Venous thromboembolic disease after total hip and knee arthroplasty. Instr Course Lect (2009) 0.84

Warfarin for thromboprophylaxis following total joint arthroplasty: are patients safely anti-coagulated? J Arthroplasty (2013) 0.82

Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials. Orthopedics (2011) 0.80

Comparison of a nomogram and physician-adjusted dosage of warfarin for prophylaxis against deep-vein thrombosis after arthroplasty. J Bone Joint Surg Am (2002) 0.79

Aggressive Anticoagulation after TJA: an evaluation of the ACCP guidelines for Thromboprophylaxis. J Long Term Eff Med Implants (2007) 0.79

Readmission following total knee arthroplasty: venous thromboembolism as a "never event" is a counterproductive misnomer. J Arthroplasty (2013) 0.77

Advances in prevention of venous thromboembolic disease after elective hip surgery. Instr Course Lect (1990) 0.77

Planned Bone Resections Using an MRI-Based Custom Cutting Guide System Versus 3-Dimensional, Weight-Bearing Images in Total Knee Arthroplasty. J Arthroplasty (2014) 0.75

Metal Ion Concentrations in Young, Active Patients Following Total Hip Arthroplasty with the Use of Modern Bearing Couples. J Arthroplasty (2015) 0.75